Immune checkpoint inhibitors (ICIs) have altered the treatment paradigm across a range of
tumour types, including gastro-oesophageal cancers. For patients with any cancer type who …

Background Pre-clinical and clinical evidence suggests that simultaneous blockade of VEGF
receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration …

Despite a decrease in incidence over past decades, gastric cancer remains a major global
health problem. In the more recent period, survival has shown only minor improvement …

Objective To date, there are no predictive biomarkers to guide selection of patients with
gastric cancer (GC) who benefit from paclitaxel. Stomach cancer Adjuvant Multi-Institutional …

Background CAFs regulate the signaling of GC cells by promoting their migration, invasion,
and proliferation and the function of immune cells as well as their location and migration in …

Background Gastric cancer is currently the fourth leading cause of cancer-related death
worldwide. Gastric cancer is often diagnosed at advanced stages and the outcome of the …

Background KN026 is a novel human epidermal growth factor receptor 2 (HER2)-targeted
bispecific antibody that binds two distinct domains of HER2. We report the safety and …

Background KIAA1199 was upregulated in diverse cancers, but the association of KIAA1199
with gastric cancer (GC), the biological role of KIAA1199 in GC cells and the related …

Purpose Zolbetuximab (IMAB362) is engineered to induce antibody-dependent cell-
mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity. We evaluated ADCC …

Objective To explore the association of membrane-associated guanylate kinase inverted 1
(MAGI1) with gastric cancer (GC) and the related molecular mechanisms. Methods The …